skip to main content

HA-WBRT Memantine — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardCNS TumoursHA-WBRT MemantineSCE Medical Oncology

A patient with multiple brain metastases is selected for whole-brain radiotherapy in an NHS service. The team proposes adding memantine routinely to reduce cognitive decline, citing a North American trial. What is the current NICE NG99 position?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Do not offer memantine with WBRT unless it is part of a clinical trial

Explanation lettering: C = shown as A · D = shown as B · A = shown as C · E = shown as D · B = shown as E

B is correct under NG99. A imports non-UK practice into a NICE question; C invents a hippocampal-avoidance exception; D invents a melanoma-specific exception; E is not an anticancer treatment. The question tests current UK guidance, not whether external evidence might support a future change.

Reference: NICE NG99 brain tumours and brain metastases: recommendations (Current NICE guideline, accessed August 2026): https://www.nice.org.uk/guidance/NG99/chapter/recommendations